Lea Lippert

Lea Lippert

Auto-generated profile, based on publicly available information

Lea Lippert

Department of Congenital Heart Defects and Pediatric Cardiology German Heart Center Munich, TUM University Hospital, School of Medicine & Health, Technical University of Munich Munich Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in European Heart Journal
Verified
Journal Article
Closed access
LLLea Lippert
Lea Lippert
TBTobias Burkard
Tobias Burkard
FMFranziska Markel
Franziska Markel
VDVolker Debus
Volker Debus
FSFridrike Stute
Fridrike Stute
CWCordula Maria Wolf
Cordula Maria Wolf
Background and Aims: This study describes outcomes in a large contemporary national cohort of children and adolescents with long QT syndrome (LQTS). Methods: Data analysis of 548 paediatric LQTS patients at 12 German tertiary care centres. Primary outcome was the occurrence of a major arrhythmic event (MAE) defined as sudden cardiac death (SCD), aborted cardiac arrest (ACA) and appropriate implantable cardioverter-defibrillator (ICD) therapy before age 18 years. Results: Patients (48.9% male) presented at a median age of 6.3 (interquartile range 0.5–11.7) years with incidental findings (26.5%), symptoms (31.3%), and for cascade screening (42.2%). Primary outcome was reached in 58 patients (10.6%): SCD in 7 (1.3%), ACA in 40 (7.3%), and appropriate ICD therapy in 11 (2.0%), with an overall event rate of 1.0 per 100 patient-years at risk. During follow-up (before 18 years of age), 92.1% of patients received cardiac medication. An ICD was implanted in 73 patients (13.3%) of whom 25 (34.2%) received appropriate therapy. In multivariate analysis, the likelihood of experiencing a MAE was greater in patients with LQT3 [hazard ratio (HR) 2.5, 95% confidence interval (CI) 1.1–5.6, P = .03], syncope (HR 3.0, 95% CI 1.7–5.5, P < .01), absence of cardiac medication (HR 9.5, 95% CI 5.3–17.3, P < .01), and QTc ≥500 ms (HR 2.9, 95% CI 1.4–6.3, P < .01). In subanalyses, a pathogenic variant in the KCNH2 pore region of LQT2 patients and younger age at symptom presentation were identified as risk factors. Conclusions: Paediatric LQTS patients are at risk for life-threatening arrhythmias at <18 years of age and require a meticulous personalized clinical approach.

23 October 2025 in European Heart Journal
Verified
Journal Article
Closed access
LLLea Lippert
Lea Lippert
CWCordula Maria Wolf
Cordula Maria Wolf

30 August 2026 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
LLLea Lippert
Lea Lippert
TBTobias Burkard
Tobias Burkard
FMFranziska Markel
Franziska Markel
VDVolker Debus
Volker Debus
FSFridrike Stute
Fridrike Stute
CWCordula Maria Wolf
Cordula Maria Wolf
Introduction: Diagnosis and treatment of children and adolescents with suspected Brugada syndrome (BrS) is challenging. Aim of the study was to evaluate the applicability of current diagnostic criteria for pediatric patients with suspected BrS in the German multicenter study COGIA and to assess clinical outcome. Methods: Data analysis of 76 pediatric patients from 12 German tertiary care centers. Primary outcome was defined by the occurrence of a major arrhythmic event (MAE), secondary outcome by symptoms, pharmacotherapy and implantation of devices. MAE was defined as sudden cardiac death (SCD), aborted cardiac arrest (ACA) and appropriate implantable cardioverter‐defibrillator (ICD) therapy. Results: Criteria for BrS diagnosis were fulfilled in 39/76 pediatric patients (51.3%) according to ESC Guidelines, including 34 patients (44.7%) according to Shanghai Score. Genetic testing identified a (likely) pathogenic SCN5A variant in 31/66 tested children (47.0%) (14/30 with clinical diagnosis (46.7%) and 17/36 without clinical diagnosis (47.2%)). Twenty‐four patients (31.6%) showed a spontaneous type 1 ECG pattern, in 6 patients (7.9%) it was induced by fever. Ajmaline challenge was positive in 19/25 patients (76.0%). Syncope occurred in 15 patients (19.7%) and an ICD was implanted in 7 pediatric patients (9.2%). Four patients (5.3%) experienced a MAE (ACA), all of them fulfilling diagnostic criteria. “Symptoms at first consultation” was identified as an independent risk factor for MAE in the whole cohort (HR = 11.3, p = 0.04). Conclusion: Establishing the diagnosis of BrS remains challenging in the pediatric cohort. MAE occurred in 5.3% of patients with suspected BrS. Symptoms at first consultation increased risk for MAE. Clinical Trial Registration: The study is registered at the German Clinical Trial Register (DRKS) of the Federal Institute for Drugs and Medical Devices (BfArM), DRKS‐ID DRKS00028138.